Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

Viking Therapeutics raised $575 million following positive top-line maintenance-study results for its injectable weight-loss candidate VK2735, including $316.2 million of common stock sold at $35 per share and $258.8 million in convertible senior notes. The issuance added roughly 9 million shares to a prior 116.6 million share count, reducing EPS by an estimated 7.2%; combined with an 8.44% higher share price, earnings yield per dollar invested is estimated to be 14.4% lower. Despite dilution and the stock trading below the $35 offering price, the article views the trial data as materially de-risking maintenance dosing and supportive of the investment case.

Analysis

The relevant valuation change is not mechanical EPS dilution: VKTX remains a pre-commercial, cash-consuming asset whose value is driven by probability-adjusted peak sales, time to market, and eventual commercialization economics. The financing materially improves its ability to fund larger studies and preserve strategic flexibility, but it also raises the hurdle for per-share upside unless management converts the cash into a credible development-time advantage or a premium strategic transaction. The convertible tranche creates a potential future supply overhang; conversion price, capped-call protection, coupon, and maturity should be reviewed before treating the post-offering price as technical support.

Over the next 1-3 months, the stock’s direction should be dictated less by the maintenance dataset than by investors’ assessment of differentiation versus Eli Lilly (LLY) and Novo Nordisk (NVO): weight-loss durability, lean-mass preservation, discontinuation rates, dosing convenience, and manufacturing scalability. The oral program is the more important rerating catalyst because oral obesity treatments can materially expand the addressable market and reduce distribution friction; a merely adequate oral profile would likely compress VKTX’s strategic premium even if injectable efficacy remains competitive. Within 6-18 months, the principal question is whether VKTX becomes an acquisition candidate or must independently finance late-stage trials and commercialization, with the latter outcome requiring substantially more capital than the current raise.

Consensus may be underweighting that a well-capitalized obesity challenger can gain negotiating leverage with potential partners, while simultaneously overestimating the significance of an offering-price ‘floor.’ In biotech, a below-deal price often reflects a reset in the probability-weighted terminal value rather than a bargain signal; the thesis is falsified by weaker subsequent oral efficacy/tolerability, a material increase in discontinuations, or evidence that required Phase 3 scale pushes cash needs materially above current runway.

Key Decisions for Investors

• Do not initiate a full directional VKTX position solely because it trades below the equity-offering price; treat $35 as a technical reference, not fundamental support. Require disclosure of convertible terms and updated cash-runway guidance before sizing beyond a watch position.
• For a 6-12 month biotech sleeve, consider a small, event-driven long VKTX only after defining downside to the next clinical readout; use a 3-5% portfolio-risk budget and reduce if management indicates additional financing is needed before pivotal-program completion.
• Prefer a relative expression long VKTX / short XBI only if VKTX demonstrates sustained relative strength after financing closes and peer GLP-1 readouts remain supportive. This isolates asset-specific execution from broad biotech duration risk; exit if VKTX underperforms XBI by 15% after the financing-related selling window.
• Monitor LLY and NVO obesity trial updates, especially oral-agent efficacy and tolerability disclosures, as read-through catalysts. Evidence that incumbent oral products deliver comparable efficacy with superior convenience would weaken VKTX’s acquisition and peak-sales assumptions before its own oral data arrive.
• Set an alert for revised development spend or runway guidance implying another raise before a value-inflecting oral or pivotal-trial milestone; that would warrant avoiding or cutting the position regardless of near-term share-price recovery.